Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥18 years of age, diagnosed with Rheumatoid Arthritis~Exclusion Criteria:~* Pregnant females~* Any other clinically significant disease or disorder which, in the opinion of the investigator might put the subject at risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg Methotrexate (MTX) (Type: EXPERIMENTAL): MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
- 15 mg MTX (Type: EXPERIMENTAL): MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
- 20 mg MTX (Type: EXPERIMENTAL): MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
- 25 mg MTX (Type: EXPERIMENTAL): MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.

Based on this trial design, predict the completion outcome and termination type (if applicable).